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Adolescents and youth constitute one-third of popu-
lations in sub-Saharan Africa, and despite having 
some of the highest HIV incidence and prevalence 
rates in the world, we have very few prevention 
interventions to offer this key population.[1] Since 
the first realisation that much HIV transmission was occurring via 
heterosexual and homosexual sex, the primary prevention options 
have consisted only of sexual abstinence, including sexual debut delay, 
monogamous sex with an individual of known HIV-negative status, 
or consistent condom use. While female condoms are available, most 
reliance has been on male condoms.
Adolescents and HIV
Adolescence is a period of transition from childhood to adulthood, 
spanning the years 10 - 19, although neurodevelopmental specialists 
argue that brain and therefore psychological modelling continues 
until at least 25 years of age.[2] It is a period of immense physical, 
psychological, social and emotional growth and is characterised 
by many opportunities for experimentation, new experiences and 
consequent vulnerabilities.[3] Yet it is a time also characterised by 
limited access to information and appropriate health and prevention 
services, leading to an increased risk of acquisition of HIV and 
other infections.[4,5] Navigating this transition successfully is highly 
dependent on individual efficacy and resilience, as well as input and 
support from family, friends, schools and communities.[6]
Given these vulnerabilities, both sexual abstinence and monogamy 
have limited application throughout the period of adolescence and 
are impractical as exclusive HIV prevention interventions for youth.
In generalised epidemics, females experience much higher levels 
of HIV infection than their male counterparts in late adolescence 
and throughout the early reproductive years.[1] While behaviour 
is an important driver of infection, the risk behaviours of South 
African (SA) adolescents are not necessarily greater than those of 
adolescents elsewhere.[7] Biological differences partly explain this 
apparent contradiction, but social and structural factors also instigate 
and maintain the risk behaviours that ultimately drive the adolescent 
epidemic in SA.[8,9]
Much has been written about the high levels of sexual coercion 
and violence in SA.[10,11] Power inequality and intimate partner 
violence decrease condom use and increase the risk of HIV infection 
in adolescent females and young women.[11,12] Inequality in sexual 
relationships is further amplified when there is a significant age 
difference between the two parties. Older men are more likely to be 
infected with HIV than adolescents, and this may be contributing to 
sudden increases in HIV acquisition in adolescent females as they 
commence relationships with older men.
In 1990, Stein[13] advocated user-dependent prevention methods, 
particularly female-initiated and managed ones. It was thought that 
vaginal microbicides could fill this prevention gap. In 2015, we do 
not yet have a licensable vaginal microbicide, but oral pre-exposure 
prophylaxis (PrEP) is certainly a viable alternative. Oral PrEP 
involves the administration of a single antiretroviral (ARV) agent, or 
dual agents, to HIV-negative individuals prophylactically, to protect 
them from infection should they be exposed to an infective source.
Following the first study of PrEP efficacy, among men who have sex 
with men (MSM) and transgendered women (TGW) and reported in 
2010, the concept of a daily pill (emtricitabine (FTC) and tenofovir 
(TDF), sold as Truvada) to prevent HIV infection has become 
increasingly evident as a useful additional biomedical intervention to 
offer to individuals in conjunction with regular testing, counselling, 
condoms and safe lubricants.[14] 
PrEP evidence
To date there have been ten randomised controlled trials (RCTs) 
of TDF-based PrEP reporting HIV outcomes.[15] PrEP was effective 
for both men and women. The studies have involved more than 
17 000 people and have demonstrated an overall reduction in 
HIV acquisition risk of 51% (women relative risk (RR) 0.57; 95% 
confidence interval (CI) 0.34 - 0.94, and men RR 0.38; 95% CI 0.2 - 
0.6). Three studies in which there was high adherence to the study 
product (>70% of drug detection) showed that PrEP was most 
efficacious and also that HIV infection was significantly reduced in 
those studies in which drug detection levels were moderate (41 - 70% 
detection). Unfortunately in the two studies with lowest adherence 
(<40% detection), involving heterosexual women in south ern and East 
Africa, PrEP had no effect.[15-17] The reasons for the particularly low 
uptake and use of oral PrEP in these two studies have been speculated 
on elsewhere and a range of potential reasons have been suggested, 
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structural, behavioural and/or psychological. [18] Unfortunately this 
has led to some controversy around the effectiveness of oral PrEP in 
black African women. It is important to note, however, that two of the 
three studies considered by the US Food and Drug Administration 
(FDA) prior to licensure of PrEP as a prevention modality included 
women from Uganda, Kenya and Botswana.[15] As a consequence, in 
2012 the FDA approved TDF/FTC PrEP for men and women at risk 
of sexual acquisition of HIV. The South African Medicines Control 
Council is currently considering this ARV combination for a similar 
indication.
The critical component of PrEP’s success is that people actually 
take it. The current recommendation in all guidelines is to aim for 
a daily dose of the single combination tablet during periods when 
sexual HIV exposure is possible.[15,19] The scientific rationale is that 
systemic drug levels will influence tissue drug levels at the site where 
HIV contact may occur. This applies to vaginal, penile and rectal 
mucosa. As a result of this extensive evidence base, the World Health 
Organization (WHO) has just included oral PrEP as an additional 
prevention choice as part of combination prevention for people 
at substantive risk in its 2015 comprehensive treatment and care 
guidelines.[15] Table 1 lists all ten randomised controlled trials to date 
and highlights those in which age was delineated.
In addition, for some time the WHO has recommended demon-
stration projects in various populations and settings to try to 
delineate the best distribution platforms in both high- and lower-
income settings.
Adolescents and PrEP
There is a dearth of literature examining attitudes to oral PrEP use 
among adolescents globally. This scarcity is even more pronounced 
in sub-Saharan Africa. Most of the research on attitudes among youth 
and adolescents has been done in the USA, with young men who have 
sex with men (YMSM). Table 2 describes some of the cited literature.
Generally, knowledge of PrEP was limited, 27 - 38% of study 
participants having heard of PrEP and 1 - 1.5% having used it,[20,21] 
with many expressing a desire for more information.[22,23] Knowledge 
was found to be associated with higher education, recent HIV testing 
and gay identity,[21] as well as increased age, having had a sexually 
transmitted infection and having health insurance.[20] In all studies, 
there was generally a positive attitude towards PrEP and a willingness 
Table 1. Randomised controlled trials comparing oral PrEP with placebo
Trial name and 
location No. enrolled Age (years), median (range) Study population No. aged <25 years Efficacy outcome
FEM-PrEP
Daily
2 120 23 (18 - 35) WSM 1 213 Stopped for futility
iPrEx
Daily
2 499 27 (18 - 67) MSM/TGW 1 153, no significant 
difference in ages
44%
Partners PrEP
Daily
4 758 33 W, 34 M (18 - 65) Serodiscordant couples 583, no significant 
difference between 
women <25 and >25 
years
75%
TDF2
Daily
1 219 25 (18 - 39) Heterosexual men and 
women
<21 yrs: 25 62%
West African study 536 Unknown Women Unknown 65% efficacy
Stopped early for 
structural reasons
Voice, MTN-003
Daily gel v. oral 
5 029 25 (18 - 45) WSM Unknown Stopped for futility
US safety study, 
CDC 4323
Daily
400 39 (18 - 60) MSM Unknown TVD detected in 
50% of people who 
seroconverted and 
in 81% of those 
who did not
Ipergay
Pericoital
414 35 (29 - 43) MSM 86% efficacy
Placebo arm 
stopped early 
owing to positive 
results 
Bangkok, IDU 
study
Daily
2 413 31 (20 - 60) PWID 1 033 <30 49% 
IAVI, Kenya
Pericoital v. daily
72 26 (18 - 46) MWSM Unknown MEMS cap 
adherence 83% in 
daily arm 
IDU = intravenous drug users; IAVI = International AIDS Vaccine Initiative; WSM = women who have sex with men; PWID = people who inject drugs;  
MWSM = men who have sex with women and men; MEMS cap = medication event monitoring system caps.
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to use it. Nonetheless, barriers to use were raised. One of the most 
significant concerns was possible side-effects of the drug,[22,24] with 
36% of participants in one study reporting that they would not use 
PrEP for this reason.[20] Other barriers included the regimen burden 
and uncertainty regarding ability to adhere to a daily pill and regular 
check-ups,[23-25] the partial efficacy of PrEP,[24,25] access and cost 
issues[22,23] and low perceived risk of HIV infection.[24] In addition, 
stigma was identified as a potential barrier in terms of being seen 
taking HIV treatment medication, as well as the association of taking 
PrEP with high-risk sexual behaviour and groups.[23,24] In contrast, 
others reported that they would be proud to take PrEP[24] and that 
it was well suited to certain situations and people (serodiscordant 
couples, people who found it difficult to adhere to condom use, those 
in casual sexual relationships).[22,23,25]
Given the differences in social context between YMSM in the USA 
and adolescents in SA, these data are not necessarily applicable to 
SA. Very little research has examined these issues in SA adolescents 
so far. Acceptability, interest, concerns and preferences regarding 
ARV-based prevention in pill, gel and injectable format have been 
explored in young women in SA and female sex workers and 
serodiscordant couples in Kenya.[26] With an overall sample of 36, 
two focus groups with adolescent girls (14 - 17 years) and two with 
young women (18 - 24 years) were conducted in SA. All groups 
expressed strong interest in PrEP use. Interestingly, adolescent girls 
felt that PrEP would be obtainable with privacy more easily than 
condoms, enhancing its appeal. Young women were enthusiastic, 
but concerned about the interactions with drugs and alcohol and 
also the challenges of adherence while under the influence of 
substances (often preceding sex). In addition, they speculated that 
ultimately products would not be used with trusted partners (much 
like condoms), thus making them no more effective. In terms of 
formulation preference, adolescents noted that all formulations 
presented adherence challenges. They felt that daily pills could be 
taken or used more easily than vaginal gel (coitally dependent), as 
sex was difficult to predict, but had concerns around swallowing 
pills and the impact on urine smell. Some preferred the coitally 
dependent gel as a less burdensome regimen, although they felt that 
it would be unpleasant to insert and might smell, while injections if 
given in depot form were viewed as painful. Among young women, 
those who preferred pills felt that they were safer than injections and 
more private than gel use, but others had concerns about daily pill 
adherence. Some preferred the injection owing to familiarity with the 
injectable contraceptive, and felt it was safer, longer lasting, private 
and difficult to forget about. One other study examined willingness 
to use PrEP among young women in SA as part of a global survey of 
1 790 participants from seven countries;[27] 124 young women (18 - 
24 years) from SA participated. In contrast to most other subgroups, 
side-effects, cost and the need for regular HIV testing posed 
higher barriers to use in this subgroup. With regard to the relative 
importance of key PrEP attributes, young SA women rated route of 
administration most highly, followed by frequency of HIV testing, 
time spent obtaining PrEP, dispensing site and frequency of pick up. 
A bimonthly injection in the buttocks was most preferred, with HIV 
testing 6-monthly. These studies are limited by their hypothetical 
nature, but highlight the importance of choice and convenience in 
meeting the needs of different young women in SA.
All ten randomised controlled PrEP studies exclusively included 
people aged >18 years, and only three stratified trial populations into 
younger (<25 years) and older.[15] In those studies, sexual and other 
behaviours were riskier in the younger group, but adherence and 
subsequently PrEP effectiveness were reduced. One of the studies 
in this group is the Global iPrEx study performed in MSM.[14] A 
subanalysis of the younger participants (18 - 24 years), who made up 
almost half of the overall cohort, demonstrated that those aged <25 
years were  3.74 times (95% CI 2.40 - 5.82) less likely to show drug 
detection in the blood (p<0.001) compared with those aged >25 years. 
The incidence of HIV per 100 person-years among young MSM was 
3.06 in the TDF/FTC group and 4.24 in the placebo group.[28]
The US-based Adolescent Trials Network (ATN) has reported on 
feasibility, safety and adherence in PrEP studies in the young MSM 
population (18 - 22 years) in the USA as part of Project PrEPare. 
ATN 082 enrolled 68 individuals (mean age 19.9 years) in a placebo-
controlled study in which 58 individuals were randomised to a 
behavioural intervention alone or the behavioural intervention either 
with TDF/FTC or placebo.[29] Self-reported medication adherence 
averaged 62% (range 43 - 83%), while rates of detectable plasma 
tenofovir ranged from 63.2% to 20% (weeks 4 - 24). The most 
commonly reported reasons for missing doses included being away 
from home (60%), forgetting (50%) and being too busy (47%).[29]
ATN 110 enrolled 200 MSM aged 18 - 22 years who were offered 
the same behavioural intervention with oral PrEP but in an open-
label manner. PrEP was well tolerated with minimal side-effects. 
While PrEP drug levels commensurate with a prevention-efficacious 
dose of >4 pills per week were seen in >50% of blood samples at week 
4, this had reduced by week 48, with marked differences in consistent 
adherence by ethnicity. Participants who reported condomless sex 
were more likely to be adherent.[30] This study has an ongoing 
‘brother’ study in 15 - 19-year-olds, and adherence and feasibility data 
from this adolescent cohort are eagerly awaited in 2016 (ATN 113).
An optimistic picture is emerging from the open-label extensions 
of the randomised trials and the demonstration studies now in the 
field, the most promising of these being the recent PROUD (MSM) 
and Partners PrEP open-label extensions and demonstration studies 
(discordant black African couples).[31-33]
A recent study known as ADAPT HPTN 067, conducted in Cape 
Town, SA, randomised 179 heterosexual women into three arms 
of self-administered daily, event-driven and intermittent TDF/FTC 
PrEP over a 24-week period.[34] The ‘coverage’ of sexual events with 
PrEP taking was measured along with actual PrEP blood levels. The 
coverage of sexual events, reported adherence and blood drug levels 
of the women in the daily arm were better than those in the other 
intermittent arms. In addition, overall adherence in the daily arm was 
good at 10 and 30 weeks of follow-up, and similar between younger 
and older participants.[34] PrEP is feasible in younger individuals.
These recent open-label studies suggest that if individuals are told 
that an intervention such as PrEP works, not only are they more likely 
to take it, but also those most at risk self-identify.
TDF and FTC are two ARV agents with a relatively clean safety 
profile. With many patient-years of exposure worldwide, both are 
regarded as a safe combination in people on HIV treatment, and 
they form part of the triple, single-pill antiviral agent currently 
Table 2. PrEP-related research
Reference Type of research Population studied
Bauermeister et al.[20] Quantitative YMSM (18 - 24 years)
Kubicek et al.[22] Qualitative YMSM (18 - 25 years)
Pérez-Figueroa et al.[23] Qualitative YMSM (18 - 21 years)
Rucinski et al.[21] Quantitative YMSM (18 - 40 years)
Smith et al.[24] Qualitative YMWSM (18 - 24 years)
Mustanski et al.[25] Quantitative MSM (16 - 20 years)
YMWSM = young men who have sex with women and men.
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being dispensed to millions of HIV-positive South Africans. Of 
note, all the above PrEP studies in normal healthy individuals also 
had an unremarkable safety profile. Adverse events were mild and 
minimal, occurring in the minority and mostly in the first month 
of exposure. These self-limiting adverse events included headaches, 
bloating, nausea and mild diarrhoea. Some of the studies noted 
non-progressive, subclinical declines in renal functioning and bone 
mineral density, none of which caused clinical events.[14] Another 
theoretical risk is that of HIV-resistance mutations occurring when 
breakthrough HIV infection occurs in the face of inadequate PrEP 
drug levels. This phenomenon has not occurred in the RCTs to 
date. [15] As PrEP scale-up starts in earnest, adverse events, safety and 
the threat of resistance will need to be closely monitored.
If a pill a day in the form of oral PrEP is an intervention that can 
be used by young women and men discreetly and independently, 
and can significantly reduce HIV acquisition, we urgently need to 
find out how to make this available to the young SA individuals who 
would benefit most, and in such a way that would derive the greatest 
impact.[35,36]
Recommendations
One of the quickest ways to get oral PrEP into the adolescent 
community safely and effectively would be to initiate a number of 
projects in a number of settings and from a variety of distribution 
platforms involving SA adolescent users. Unfortunately, of the 
many demonstration projects around the world that are currently 
underway or imminently planned, very few involve adolescent 
populations.[37]
One open-label study called Pluspills is part of the broader 
CHAMPS-SA project of the Desmond Tutu HIV Foundation and is 
currently enrolling 150 young men and women aged 15 - 19 years 
in Cape Town and Soweto. Data on acceptability, use and adherence 
will be available in October 2016. Another HPTN-sponsored study is 
also undergoing regulatory review and will involve 400 young black 
African women aged 15 - 24 years. It is expected to launch by 2016.
In addition, a number of agencies are considering combination 
prevention projects among adolescent girls and young women that 
could inform scale-up of PrEP in southern and eastern Africa. These 
include a multi-institutional project funded by USAID and the very 
exciting DREAMS project spearheaded by PEPFAR and various 
private funders in PEPFAR-sponsored African countries.[38,39]
There are a number of gaps in our knowledge of how best to utilise 
this intervention among adolescents, and these could be answered by 
well-constructed and monitored field projects. Table 3 lists some of 
these outstanding questions.
Future directions
Oral PrEP is available and has a growing evidence base for its wider 
deployment. Unlike ARV treatment, oral PrEP is an intervention that 
individuals would need and use only during periods of HIV risk. 
The analogy is malaria prophylaxis, where antimalarial prophylactic 
agents are only taken during periods of exposure to potentially 
infected mosquitoes. In the case of adolescents this may cover the 
periods of sexual experimentation and when permanent sexual 
partners have not yet been established and partner status is unknown, 
which it is hoped would also align with the highest incidence rates.
In addition, other longer-acting modalities are in clinical develop-
ment that may assist with daily adherence, something that has been 
identified as difficult in adolescent populations. Some of these 
modalities include a vaginal ring that needs only monthly admini-
stration, and long-acting injectable agents that may be dispensed 
every 2 months. Table 4 lists some of these PrEP modalities and when 
efficacy data to support their use may be available. The analogy is 
that of contraception, where both choice of modality and options for 
prolonged dosing intervals have been shown to increase adherence 
and effectiveness.
Table 4. Some of the newer alternative modalities in the 
pipeline
Modality Study Results expected
Dapivirine vaginal ring ASPIRE MTN 020
Phase 3
Q4 2015/Q1 2016
The Ring Study 
IPM 027
Phase 3
Q4 2016
Cabotegravir LA PrEP
8-week injectable PrEP
HPTN 077
Phase 2a
Q3 2017
TMC278 (rilpivirine) 
LA PrEP
8-week injectable PrEP
HPTN 076
Phase 2a
Q4 2017
Cabotegravir LA PrEP v. 
oral PrEP v. placebo 
HPTN 083
Phase 2b
To be commenced 
LA = long acting; Q = quarter of year.
Table 3. Knowledge gaps in PrEP provision for adolescents
Questions in provision of oral PrEP to adolescents 
Behavioural
Acceptability of PrEP
Willingness to use daily PrEP
 Adherence to/persistence with programme (monitoring, testing, 
counselling)
Adherence to daily pills
Stigma
Sexual disinhibition with condom migration 
Biomedical
Tolerability
Toxicities – impact on bone mineralisation
More STIs? – mucosal activation
More frequent sex, sex partners
Less frequent sex? Loading dose
Size and smell of pills
Increased unwanted pregnancy and STIs
Structural
Which health platform? SRH, ANC, FP, PHC 
Regular testing
Adolescent-friendly services
Confidentiality/privacy
Social
Enablers to assist with daily adherence, e.g. SMS messaging
 Enablers to assist with integration into programme, e.g. social 
media/networks
STIs = sexually transmitted infections; SRH = sexual and reproductive health;  
ANC = antenatal clinic; FP = family planning; PHC = primary healthcare;  
SMS = text message.
REVIEW
911       November 2015, Vol. 105, No. 11
Conclusions
Apart from sexual abstinence, to date we have been able to offer 
young women only the male latex condom as protection against HIV 
infection. Given some of the difficulties described above, it is less 
than surprising that in 2015 we see incidence rates among young 
SA women that are the highest in the world. Young people, and 
especially young women, need more prevention options to protect 
themselves.[36] Oral PrEP certainly is one such modality that has great 
promise. Offering this intervention to our adolescent and young 
adult population has the potential to make a significant dent in our 
epidemic.
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